Browse By: Country ι Category ι Tag
Home  »  Ovarian Cancer

Ovarian Cancer Market Research Reports

More

Global Ovarian Cancer Drugs Market Report 2016
Roche Boehringer Ingelheim Amgen AstraZeneca GlaxoSmithKline ABRAXANE Doxil Exelixis DelMar Pharmaceuticals Inc Bristol-Myers Squibb Celgene Alkeran Lynparza Novartis Pharmaceuticals Corp Clovis Oncology Alza Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Ovarian Cancer Drugs in these regions, from 2011 to 2021 (forecast), like North America China Europe Japan Latin America India Row Split by Product Types, with production, revenue, price, market share and growth rate of each type, can be divided into Oral Therapy Injectable Therapy Others Split by applications, this report focuses on consumption, market share and growth rate of Ovarian Cancer Drugs in each application, can be divided int
Published Date: Feb 2017
Published By: QYResearch

Price: $2955
Ovarian Cancer - Treatment Landscape & Competitive Analysis, 2017
Note: This report will be delivered to the client in 1-2 business days Report Highlights: • The new report, provides a Ovarian Cancer Treatment Landscape across the globe • The report provides profiles of the marketed drug which includes the product description, cost of treatment, development partner, patent expiry date, sales data etc. • Comparative analysis of marketed drugs by therapy, cost of treatment and Therapeutic Class. • Coverage of the Ovarian Cancer Phase III and Pre-registration Drugs Analysis by product type, molecule type, route of administration, Median Progression Free Survival • The report reviews key players involved in the therapeutics development for Ovarian Cancer and also provide market barriers, market drivers and opportunities • Provides Phase III produ
Published Date: Feb 2017
Published By: DelveInsight

Price: $2450
Global Ovarian Cancer Partnering 2010 to 2017
• Trends in partnering deals • Top deals by value • Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understanding and access to the partnering deals and agreements entered into by the world’s leading healthcare companies. The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation o
Published Date: Feb 2017
Published By: Current Partnering

Price: $1495
Global Ovarian Cancer Drugs Market Research Report 2016
Production, means the output of Ovarian Cancer Drugs Revenue, means the sales value of Ovarian Cancer Drugs This report studies Ovarian Cancer Drugs in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering Roche Boehringer Ingelheim Celgene Amgen AstraZeneca GlaxoSmithKline ... Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Ovarian Cancer Drugs in these regions, from 2011 to 2021 (forecast), like North America Europe China Japan Split by product type, with production, revenue, price, market share and growth rate of
Published Date: Jan 2017
Published By: QYResearch

Price: $2900
Metastatic Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Metastatic Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Metastatic Ovarian Cancer Report is to understand the market and pipeline status of the drugs around the Metastatic Ovarian Cancer to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Metastat
Published Date: Jan 2017
Published By: DelveInsight

Price: $2000
Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Ovarian Cancer Report is to understand the market and pipeline status of the drugs around the Ovarian Cancer to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Ovarian Cancer. While the leading brands,
Published Date: Jan 2017
Published By: DelveInsight

Price: $2000
Metastatic Ovarian Cancer-Pipeline Insights, 2017
DelveInsight’s, “ Metastatic Ovarian Cancer-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Metastatic Ovarian Cancer. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Metastatic Ovarian Cancer. DelveInsight’s Report also assesses the Metas
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Epithelial Ovarian Cancer-Pipeline Insights, 2017
DelveInsight’s, “ Epithelial Ovarian Cancer-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Epithelial Ovarian Cancer. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Epithelial Ovarian Cancer. DelveInsight’s Report also assesses the Epith
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Ovarian Cancer-API Insights, 2017
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have posi
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Ovarian Cancer - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer – Pipeline Review, H2 2016, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape. Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian C
Published Date: Dec 2016
Published By: Global Markets Direct

Price: $2500
Epithelial Ovarian Cancer - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epithelial Ovarian Cancer – Pipeline Review, H2 2016, provides an overview of the Epithelial Ovarian Cancer (Oncology) pipeline landscape. Ovarian epithelial cancer is a disease in which malignant (cancer) cells form in the tissue covering the ovary. Early ovarian cancer may not cause any symptoms. When symptoms do appear, ovarian cancer is often advanced. Symptoms may include pain or swelling in the abdomen, pain in the pelvis and gastrointestinal problems, such as gas, bloating, or constipation. There are different types of treatment for patients with ovarian epithelial cancer such as surgery, radiation therapy, and chemotherapy. Report Highlights Global Markets Direct's Pharmaceutical a
Published Date: Nov 2016
Published By: Global Markets Direct

Price: $2000
Metastatic Ovarian Cancer - Pipeline Review, H2 2016
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Ovarian Cancer – Pipeline Review, H2 2016, provides an overview of the Metastatic Ovarian Cancer (Oncology) pipeline landscape. Metastatic ovarian cancer is a type of cancer that originates in the ovaries, but then spreads to other areas of the body, such as the diaphragm, intestine, mentum (a fatty layer that covers and pads abdominal organs), liver or lungs. Symptoms include fatigue, getting full quickly, abdominal swelling, leg swelling, changes in bowel habits, and changes in bladder habits, abdominal pain, and shortness of breath. Metastatic ovarian cancer is often treated with a combination of therapies that can include surgery, chemotherapy and radiation therapy. Report Highl
Published Date: Oct 2016
Published By: Global Markets Direct

Price: $2000
Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016
Summary GlobalData's Medical Devices sector report, “Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" provides an overview of Ovarian Cancer Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Ovarian Cancer Diagnostic Tests pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of indu
Published Date: Sep 2016
Published By: GlobalData

Price: $4000
Global Ovarian Cancer Drugs Industry 2016, Trends and Forecast Report
The report firstly introduced the Ovarian Cancer Drugs basics: definitions, classifications, applications and industry chain overview; industry policies and plans; product specifications; manufacturing processes; cost structures and so on. Then it analyzed the world's main region market conditions, including the product price, profit, capacity, production, capacity utilization, supply, demand and industry growth rate etc. In the end, the report introduced new project SWOT analysis,investment feasibility analysis, and investment return analysis. The report includes six parts, dealing with: 1.) basic information; 2.) the Asia Ovarian Cancer Drugs industry; 3.) the North American Ovarian Cancer Drugs industry; 4.) the European Ovarian Cancer Drugs industry; 5.) market entry and investment
Published Date: Aug 2016
Published By: 9Dimen Research

Price: $2850
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Summary GlobalData's clinical trial report, “Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016" provides an overview of Metastatic Ovarian Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Ovarian Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are
Published Date: Jul 2016
Published By: GlobalData

Price: $2500
Ovarian Cancer-Pipeline Insights, 2016
Note: This report will be delivered to the client in 48 hours Report Highlights: • The new report, provides a Ovarian Cancer Landscape across the globe • The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information • Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages • Coverage of the Ovarian Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type • The report reviews key players involved in the therapeutics development for Ovarian Cancer and also provide company profiling • Pipeline products coverage based on various stages of development from NDA filings to discovery. • Pr
Published Date: Jul 2016
Published By: DelveInsight

Price: $2250
Ovarian Cancer - Market Insights, Epidemiology and Market Forecast-2020-US
Note: This report will be delivered to the client in 48 hours Scope • Report covers the disease overview, current treatment options, prescription drugs and emerging therapies. • The Report also covers the detailed global historical and forecasted epidemiological data covering United States from 2012-2020. • It also provides Market size of Ovarian Cancer for United States and forecasted Market size to 2020
Published Date: Jul 2016
Published By: DelveInsight

Price: $3250
Ovarian Cancer - Treatment Landscape & Competitive Analysis, 2016
Note: This report will be delivered to the client in 48 hours Report Highlights: • The new report, provides a Ovarian Cancer Treatment Landscape across the globe • The report provides profiles of the marketed drug which includes the product description, cost of treatment, development partner, patent expiry date, sales data etc. • Comparative analysis of marketed drugs by therapy, cost of treatment and Therapeutic Class. • Coverage of the Ovarian Cancer Phase III and Pre-registration Drugs Analysis by product type, molecule type, route of administration, Median Progression Free Survival • The report reviews key players involved in the therapeutics development for Ovarian Cancer and also provide market barriers, market drivers and opportunities • Provides Phase III products asses
Published Date: Jul 2016
Published By: DelveInsight

Price: $2450
Ovarian Cancer - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Ovarian Cancer - Pipeline Review, H1 2016’, provides an overview of the Ovarian Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe c
Published Date: Jun 2016
Published By: Global Markets Direct

Price: $2500
Epithelial Ovarian Cancer - Pipeline Review, H1 2016
Summary Global Markets Direct’s, ‘Epithelial Ovarian Cancer - Pipeline Review, H1 2016’, provides an overview of the Epithelial Ovarian Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Epithelial Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epithelial Ovarian Cancer and features dormant and discontinued projects. Global Markets Direct’s report featur
Published Date: May 2016
Published By: Global Markets Direct

Price: $2000

Back To Top